Ajufo H et al. Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis. ASH 2023;Abstract 3207.

Gerds AT et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): An updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol 2023;10(9):e735-46. Abstract

Gerds AT et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study. ASCO 2023;Abstract 7016.

Gupta V et al. Safety and efficacy of fedratinib in patients with primary (P), post-polycythemia vera (post-PV), and post-essential thrombocythemia (post-ET) myelofibrosis (MF) previously treated with ruxolitinib: Primary analysis of the FREEDOM trial. ASH 2022;Abstract 1711.

Kong T et al. Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. Am J Hematol 2023;98(7):1029-42. Abstract

Maher K et al. A global, phase 3, randomized, double-blind study to evaluate safety and efficacy of selinexor, an XPO-1 inhibitor, in combination with ruxolitinib in JAK Inhibitor-naïve myelofibrosis (XPORT-MF-034). ASH 2023;Abstract 3209.

Mascarenhas J et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 2022;139(19):9592-4. Abstract

Mascarenhas J et al. Pacritinib vs beast available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-9. Abstract

Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;7(19):5835-42. Abstract

Pemmaraju N et al. TRANSFORM-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. ASH 2023;Abstract 620.

Pemmaraju N et al. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 2022;128(13):2420-32. Abstract

Pemmaraju N et al. Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. EJHaem 2022;3(4):1345-51. Abstract

Rampal R et al. Pelabresib in combination with ruxlitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study. ASH 2023;Abstract 628.

Tantravahi SK et al. Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-naïve patients with myelofibrosis: Long-term follow-up from XPORT-MF-034 suggestive of disease modification. ASH 2023;Abstract 622.

Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 2023;401(10373):269-80. Abstract

Yacoub A et al. Long-term hematologic improvement in a patient with cytopenic myelofibrosis treated with pacritinib. JCO Precis Oncol 2023;7:e2200523. Abstract